General Information of Drug (ID: DMSWNJF)

Drug Name
Ravulizumab Drug Info
Synonyms Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210
Indication
Disease Entry ICD 11 Status REF
Paroxysmal nocturnal haemoglobinuria 3A21.0 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMSWNJF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Complement C5 (CO5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zilucoplan DM9Z4N5 Generalized myasthenia gravis 8C60 Approved [4]
Pozelimab DMTE8DC Large B Cell Lymphoma Approved [5]
Avacincaptad pegol DM1Z3Z2 Geographic atrophy 9B75 Approved [6]
SKY59 DMWOF1E Haemolytic uraemic syndrome 3A21.2 Phase 3 [7]
SB12 DMME6GJ Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [8]
Zimura DM09TVB Macular degeneration 9B78.3 Phase 3 [9]
ABP959 DMDXE4I Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [10]
Coversin DMMEAOL Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [11]
Nomacopan DML6E6G Bullous pemphigoid EB41.0 Phase 3 [12]
ALXN1720 DMOB3CI Generalized myasthenia gravis 8C60 Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eculizumab DMJGWZ7 Age-related macular degeneration 9B75.0 Approved [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [1]
HUMAN complement C5 protein (C5) TTN0GJ5 CO5_HUMAN Inhibitor [3]

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health.
3 Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217225
7 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.
8 Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729.
9 C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.
10 A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74.
11 Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258.
12 Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022 Jun 1;158(6):641-649.
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight